NO20014891D0 - Fragmenter av virusprotein 2 eller 3 fra polyomavirus, anvendt for transportering av aktive ingredienser - Google Patents

Fragmenter av virusprotein 2 eller 3 fra polyomavirus, anvendt for transportering av aktive ingredienser

Info

Publication number
NO20014891D0
NO20014891D0 NO20014891A NO20014891A NO20014891D0 NO 20014891 D0 NO20014891 D0 NO 20014891D0 NO 20014891 A NO20014891 A NO 20014891A NO 20014891 A NO20014891 A NO 20014891A NO 20014891 D0 NO20014891 D0 NO 20014891D0
Authority
NO
Norway
Prior art keywords
polyomavirus
fragments
active ingredients
virus protein
transporting active
Prior art date
Application number
NO20014891A
Other languages
English (en)
Other versions
NO20014891L (no
Inventor
Wolf Bertling
Christian Reiser
Juergen Walter
Original Assignee
November Ag Molekulare Medizin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by November Ag Molekulare Medizin filed Critical November Ag Molekulare Medizin
Publication of NO20014891D0 publication Critical patent/NO20014891D0/no
Publication of NO20014891L publication Critical patent/NO20014891L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/025Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/645Secretins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/22011Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polyamides (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
NO20014891A 1999-04-10 2001-10-08 Fragmenter av virusprotein 2 eller 3 fra polyomavirus, anvendt for transportering av aktive ingredienser NO20014891L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19916224A DE19916224C1 (de) 1999-04-10 1999-04-10 Synthetisches biologisch aktives Molekül
PCT/DE2000/000976 WO2000061616A1 (de) 1999-04-10 2000-04-03 Fragmente des virus proteins 2 oder 3 des polymavirus als fähren für wirkstoffe

Publications (2)

Publication Number Publication Date
NO20014891D0 true NO20014891D0 (no) 2001-10-08
NO20014891L NO20014891L (no) 2001-11-07

Family

ID=7904139

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014891A NO20014891L (no) 1999-04-10 2001-10-08 Fragmenter av virusprotein 2 eller 3 fra polyomavirus, anvendt for transportering av aktive ingredienser

Country Status (19)

Country Link
US (2) US7011968B1 (no)
EP (2) EP1173475B1 (no)
JP (1) JP2002544122A (no)
KR (1) KR100627935B1 (no)
CN (1) CN1346366A (no)
AT (1) ATE303401T1 (no)
AU (1) AU768669B2 (no)
BR (1) BR0011178A (no)
CA (1) CA2364536A1 (no)
CZ (1) CZ20013621A3 (no)
DE (3) DE19916224C1 (no)
EA (1) EA006631B1 (no)
HU (1) HUP0200679A2 (no)
IL (1) IL145403A0 (no)
MX (1) MXPA01010189A (no)
NO (1) NO20014891L (no)
PL (1) PL355852A1 (no)
WO (1) WO2000061616A1 (no)
ZA (1) ZA200107658B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19916224C1 (de) * 1999-04-10 2000-06-21 November Ag Molekulare Medizin Synthetisches biologisch aktives Molekül
GB2357084A (en) * 1999-12-06 2001-06-13 Amersham Pharm Biotech Uk Ltd A hydrophobic carrier peptide
DE10306789A1 (de) * 2003-02-18 2004-08-26 Responsif Gmbh Zusammensetzung zur Verabreichung an ein Lebewesen und Verfahren zur Markierung von Mitteln
US20090062237A1 (en) * 2007-06-15 2009-03-05 Mayo Foundation For Medical Education And Research Evaluating immune competence
EP2636746A1 (en) * 2012-03-06 2013-09-11 Life Science Inkubator A novel drug delivery system based on JCV-VLP
CN113278634B (zh) * 2020-11-16 2022-06-28 艾棣维欣(苏州)生物制药有限公司 一种预防和治疗默克尔细胞癌的新型疫苗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1319101C (en) 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
US4950599A (en) * 1987-01-29 1990-08-21 Wolf Bertling Method for exchanging homologous DNA sequences in a cell using polyoma encapsulated DNA fragments
GB9114003D0 (en) 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
DE656950T1 (de) * 1992-08-21 1996-03-14 Biogen Inc Tat-derivate transport polypeptide.
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
DE4335025A1 (de) 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
DE19618797C2 (de) * 1996-05-10 2000-03-23 Bertling Wolf Vehikel zum Transport molekularer Substanz
US5858648A (en) * 1996-11-04 1999-01-12 Sienna Biotech, Inc. Assays using reference microparticles
DE19916224C1 (de) * 1999-04-10 2000-06-21 November Ag Molekulare Medizin Synthetisches biologisch aktives Molekül

Also Published As

Publication number Publication date
ATE303401T1 (de) 2005-09-15
JP2002544122A (ja) 2002-12-24
KR100627935B1 (ko) 2006-09-22
PL355852A1 (en) 2004-05-31
MXPA01010189A (es) 2003-07-21
EP1173475A1 (de) 2002-01-23
NO20014891L (no) 2001-11-07
US7011968B1 (en) 2006-03-14
EA200101066A1 (ru) 2002-04-25
KR20020007361A (ko) 2002-01-26
CA2364536A1 (en) 2000-10-19
HUP0200679A2 (en) 2002-06-29
ZA200107658B (en) 2002-07-22
EP1586582A1 (de) 2005-10-19
EA006631B1 (ru) 2006-02-24
BR0011178A (pt) 2002-05-21
CN1346366A (zh) 2002-04-24
DE19916224C1 (de) 2000-06-21
IL145403A0 (en) 2002-06-30
EP1173475B1 (de) 2005-08-31
DE50011068D1 (de) 2005-10-06
US20070009921A1 (en) 2007-01-11
DE10080849D2 (de) 2002-06-27
CZ20013621A3 (cs) 2002-05-15
WO2000061616A1 (de) 2000-10-19
AU4285000A (en) 2000-11-14
AU768669B2 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
DE69713112D1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
DE59410380D1 (de) Endosomolytisch wirksame partikel
CY1107051T1 (el) Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους
ES2121479T3 (es) Solucion estabilizadora para proteinas y peptidos.
TR199802534T2 (xx) Leptin (OB Protein) fragmanlar�
DK0848720T3 (da) Antagonister af den onkogene aktivitet af proteinet Mdm2 og deres anvendelse ved behandling af cancere
PT1079849E (pt) Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
DE69322872D1 (de) Vakzine gegen immunodefizienz-virus der katze (kiv)
NO20014891D0 (no) Fragmenter av virusprotein 2 eller 3 fra polyomavirus, anvendt for transportering av aktive ingredienser
DE69508382D1 (de) Peptomere mit erhöhter immunogenizität
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv
KR940007059A (ko) 변형된 혈소판 인자-4
ES2122921B1 (es) Proteinas recombinantes de fusion del virus reproductivo y respiratorio porcino (prrsv) y su empleo en diagnostico.
FR2766489B1 (fr) Derives de streptogramines, leur preparation et les compositions qui les contiennent
DE69008701D1 (de) Ein b-epitop des hüllglykoproteins eines retrovirus und ein t-epitop eines anderen proteins dieses retrovirus enthaltende zusammensetzung.
TR200002611T2 (tr) Beta-lipotropin ve kullanımları
ATE346604T1 (de) Verwendung von histonen zur herstellung von arzneimitteln
ATE282704T1 (de) Isolierte und gereinigte humane lösliche guanylylcyclase alpha1/beta1 (hsgc alpha1/beta1)
RU94046405A (ru) Птг-соединения и содержащий их фармацевтический состав, способ получения желаемых полипептидов, нуклеотидная последовательность, бактериальный вектор экспрессии, бактериальные хозяйские клетки и составной белок
RU99107378A (ru) Применение белков в качестве антиретровирусных агентов
FR2792639B1 (fr) Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application